Support For Patients & Caregivers

Integrating ADT into their Lives

We support your counseling efforts as you teach, guide, and support
your patients throughout their advanced prostate cancer treatment.

LIVE HEALTHY MAGAZINE

A healthy lifestyle magazine designed for advanced prostate cancer patients undergoing androgen deprivation therapy

Download

ADT = androgen deprivation therapy.

Firmagon Connect

Helping You Help Your Patients

Enroll your practice in FIRMAGON Support Services.* Let us verify eligibility and coverage for your patients so your team can spend time where it matters most—on patient care

Medical and pharmacy benefits investigation
Practice support guidance
Hormone therapy education

Enroll Now

To enroll by telephone, call 877-971-3778.

The Reimbursement & Support Portal does not file claims or appeal claims and cannot guarantee that you will be successful in obtaining reimbursement. Third-party payment for medical products and services is affected by numerous factors, none of which can be anticipated or resolved by the Reimbursement & Support Portal.

Important Safety Information

FIRMAGON is contraindicated in patients with a known hypersensitivity to degarelix or to any of the product components and in women who are or may become pregnant. FIRMAGON can cause fetal harm when administered to a pregnant woman.

Hypersensitivity reactions, including anaphylaxis, urticaria, and angioedema, have been reported post-marketing with FIRMAGON. In case of a serious hypersensitivity reaction, discontinue FIRMAGON immediately if the injection has not been completed, and manage as clinically indicated. Patients with a known history of serious hypersensitivity reactions to FIRMAGON should not be re-challenged with FIRMAGON.

Long-term androgen deprivation therapy (ADT) prolongs the QT interval. Physicians should consider whether the benefits of ADT outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA or Class III antiarrhythmic medications.

Therapy with FIRMAGON results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after FIRMAGON may be affected. The therapeutic effect of FIRMAGON should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.

The most common adverse reactions (≥10%) during FIRMAGON therapy included injection site reactions (eg, pain, erythema, swelling, or induration), hot flashes, increased weight, fatigue, and increases in serum levels of transaminases and gamma-glutamyltransferase. The majority of adverse reactions were Grade 1 or 2; 1% or less were Grade 3/4. Injection site reactions were mostly transient, of mild to moderate intensity, occurred primarily with the starting dose, and led to few discontinuations (<1%).

Indication

FIRMAGON^® is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.

Support For Patients & Caregivers

Integrating ADT into their Lives

FIRMAGON® (degarelix for injection) STARTER KIT

Firmagon Connect

Helping You Help Your Patients

FIRMAGON^® (degarelix for injection) STARTER KIT